Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker
- 29 April 2009
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 65 (9) , 887-894
Abstract
To investigate the impact of cytochrome P450 2C19 (CYP2C19) phenotypes on escitalopram metabolism and to evaluate pupillometry as a serotonergic biomarker. This was a double-blind, crossover design study with single and multiple doses of 10 mg escitalopram and placebo in panels of CYP2C19 extensive (EM) and poor metabolisers (PM). Pupillometry was measured by a NeurOptics Pupillometer-PLR. Five PM and eight EM completed the study. The CYP2C19 phenotype significantly affected the metabolism of escitalopram. The area under the time–plasma concentration curve (AUC0-24) was 1.8-fold higher in PM than in EM after both single and multiple doses. Escitalopram treatment did not affect the maximum pupil size, but it did statistically significantly decrease the relative amplitude of the pupil light reflex compared to the placebo; this effect was equal in both phenotype groups. The CYP2C19 polymorphism affects escitalopram metabolism, but the difference does not justify dose adjustment. The puzzling results from pupillometry can be due to interplay between a central and a local serotonergic effect. Based on these results, pupillometry can not be recommended as a serotonergic biomarker.Keywords
This publication has 22 references indexed in Scilit:
- Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspectsPharmacology & Therapeutics, 2007
- The importance of serotonin and noradrenaline in anxietyInternational Journal of Psychiatry in Clinical Practice, 2007
- The Pharmacology of Citalopram Enantiomers: The Antagonism by R‐Citalopram on the Effect of S‐Citalopram*Basic & Clinical Pharmacology & Toxicology, 2006
- Heterozygous Mutation in CYP2C19 Significantly Increases the Concentration/Dose Ratio of Racemic Citalopram and Escitalopram (S-citalopram)Therapeutic Drug Monitoring, 2006
- Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy SwedesBritish Journal of Clinical Pharmacology, 2003
- CYP2C19 genotype and phenotype determined by omeprazole in a Korean populationPharmacogenetics, 1996
- Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotypePharmacogenetics, 1995
- Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation PolymorphismsTherapeutic Drug Monitoring, 1993
- The pharmacological effect of citalopram resides in the (S)-(+)-enantiomerJournal of Neural Transmission, 1992
- On central effects of serotonin re-uptake inhibitors: Quantitative EEG and psychometric studies with sertraline and zimelidineJournal of Neural Transmission, 1986